Breaking News Instant updates and real-time market news.

NFLX

Netflix

$115.21

0.18 (0.16%)

, AGN

Allergan

$192.85

1.07 (0.56%)

10:13
11/21/16
11/21
10:13
11/21/16
10:13

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Buy at Brean Capital. 2. Allergan (AGN) initiated with a Market Perform at William Blair. 3. Myovant Sciences (MYOV) was initiated with an Overweight at Barclays, an Outperform at JMP Securities, an Outperform at Baird, a Buy at Citi, and an Outperform at Cowen. 4. RA Pharmaceuticals (RARX) was initiated with a Buy at Jefferies, a Buy at SunTrust, and an Outperform at Credit Suisse. 5. ZTO Express (ZTO) was initiated with a Buy ratings at Citi and Goldman and an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

NFLX

Netflix

$115.21

0.18 (0.16%)

AGN

Allergan

$192.85

1.07 (0.56%)

MYOV

Myovant Sciences

$10.82

-0.43 (-3.82%)

RARX

RA Pharmaceuticals

$13.29

-0.12 (-0.89%)

ZTO

ZTO Express

$16.57

0.27 (1.66%)

  • 28

    Nov

  • 29

    Nov

  • 29

    Nov

  • 05

    Dec

NFLX Netflix
$115.21

0.18 (0.16%)

11/18/16
MACQ
11/18/16
NO CHANGE
MACQ
Netflix mentioned positively at M Science
11/18/16
WBLR
11/18/16
NO CHANGE
WBLR
Outperform
William Blair calls Netflix net-neutrality fears overblown
Shares of Netflix are down about 8% since President-elect Donald Trump won the election, in part due to growing concerns about potential changes to net-neutrality, William Blair analyst Ralph Schackart tells investors in a research note. Netflix already has paying arrangements in place with the major Internet Service Providers in the United States, and any potential reversal of net-neutrality rules by the Federal Communications Commission would likely not supersede agreements that are already established, Schackart contends. As such, the analyst believes any changes to the rule would likely be a nonevent for Netflix. He remains a long-term believer in Netflix's original content strategy, the "inevitable" shift to over-the-stop streaming, and the company's ability to grow revenue faster than content costs. Schackart's "base case" valuation methodology points to a mid-$140s stock price and his "bull case" has a stock price of $185. Netflix closed yesterday at $115.03.
11/21/16
BMUR
11/21/16
INITIATION
Target $145
BMUR
Buy
Netflix initiated with a Buy at Brean Capital
Brean Capital analyst Alan Gould started Netflix with a Buy rating and $145 price target. The company has created an "unstoppable lead" in the internet TV business and is positioned to dominate the business long term, Gould tells investors in a research note. He believes Netflix over the next 15 years can attract 300M global subscribers and generate over $25 of earnings per share. The stock closed Friday up 18c to $115.21.
11/18/16
RBCM
11/18/16
NO CHANGE
RBCM
Internet stock weakness creates buying opportunity, says RBC Capital
EBC Capital analyst Mark Mahaney says that the 5%-10% decline in Internet stocks since the election has created more attractive long-term opportunities. The analyst does not expect the Trump Administration's policies to have a major impact on the fundamentals of the Internet sector. His favorite large-cap names in the sector are, in order, Netflix (NFLX), Facebook (FB), and Priceline (PCLN). His favorite small-cap names are, in order, Yelp (YELP), Criteo (CRTO), and GoDaddy (GDDY).
AGN Allergan
$192.85

1.07 (0.56%)

11/03/16
JPMS
11/03/16
NO CHANGE
JPMS
JPMorgan calls Lilly, Bristol-Myers, Allergan favorite pharma majors
Following a "challenging" Q3 earnings season for the major pharmaceuticals companies, JPMorgan analyst Chris Schott said pricing continues to be a major overhang on the space. However, he believes these and other challenges are "increasingly well reflected" in both earnings and sector multiples and recommends companies early in new product launch cycles. Coming out of the earnings season, Schott named Eli Lilly (LLY), Bristol-Myers (BMY) and Allergan (AGN) as his favorite names in the large-cap pharma space.
11/04/16
UBSW
11/04/16
NO CHANGE
Target $240
UBSW
Buy
Allergan price target lowered to $240 from $300 at UBS
UBS analyst Marc Goodman lowered his price target on Allergan to $240 from $300 following disappointing Q3 results and a lowering of his estimates. However, Goodman reiterated his Buy rating on Allergan shares, on the belief it is still a good growth story, has an efficient tax structure and robust pipeline, and has the potential to put up double digit earnings growth for the rest of the decade.
11/03/16
LEER
11/03/16
NO CHANGE
Target $266
LEER
Outperform
Allergan price target lowered to $266 from $294 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Allergan to $266 from $294 after the company reported quarterly results modestly missing revenue and EPS targets, with a slowdown in revenue for some of the company's established products leading to a 2016 guidance rebasing. However, Gerberry reiterates an Outperform rating on the shares as he came away from the quarter update encouraged by robust Q3 sales growth from Allergan's more differentiated/cash pay growth drivers.
11/21/16
WBLR
11/21/16
INITIATION
Target $209
WBLR
Market Perform
Allergan initiated with a Market Perform at William Blair
William Blair analyst Tim Lugo started Allergan with a Market Perform rating and $209 price target. The analyst views the company as high quality but sees headwinds in 2017 and 2018. Renewed competition for Botox could weigh on out-year estimates while a Namenda generic could come sooner than expected, Lugo tells investors in a research note.
MYOV Myovant Sciences
$10.82

-0.43 (-3.82%)

11/21/16
COWN
11/21/16
INITIATION
Target $11
COWN
Outperform
Myovant Sciences initiated with an Outperform at Cowen
Cowen analyst Phil Nadeau initiated Myovant Sciences with an Outperform rating and $11 price target as he believes its Relugolix drug potential is undervalued. He noted it reported a strong proof of concept and should enter pivotal programs in 1H 2017, while projecting peak sales of more than $2B.
11/21/16
JMPS
11/21/16
INITIATION
Target $23
JMPS
Outperform
Myovant Sciences initiated with an Outperform at JMP Securities
JMP Securities analyst Jason Butler initiated Myovant Sciences with an Outperform and a $23 price target. The analyst said lead asset, relugolix, is a potent oral GnRH antagonist entering Phase 3 development in women with uterine fibroids and endometriosis, and in men with advanced prostate cancer. He views this as a substantially de-risked asset with established mechanistic rationale and compelling Phase 2 results in Japan with block buster sales opportunities.
11/21/16
BARD
11/21/16
INITIATION
Target $20
BARD
Outperform
Myovant Sciences initiated with an Outperform at Baird
Baird analyst Brian Skorney initiated Myovant Sciences with an Outperform and a $20 price target.
11/21/16
SBSH
11/21/16
INITIATION
Target $17
SBSH
Buy
Myovant Sciences initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Myovant Sciences (MYOV) with a Buy rating and $17 price target. The analyst sees upside if the company meets enrollment timelines through 2017. Myovant's Relagolix is validated by Neurocrine's (NBIX) Elagolix, but may have greater convenience and efficacy, Karnauskas contends.
RARX RA Pharmaceuticals
$13.29

-0.12 (-0.89%)

11/21/16
BMOC
11/21/16
INITIATION
Target $26
BMOC
Outperform
RA Pharmaceuticals initiated with an Outperform at BMO Capital
BMO Capital analyst Ian Somaiya started RA Pharmaceuticals with an Outperform rating and $26 price target.
11/21/16
RHCO
11/21/16
INITIATION
Target $32
RHCO
Buy
RA Pharmaceuticals initiated with a Buy at SunTrust
SunTrust analyst Yatin Suneja started RA Pharmaceuticals with a Buy rating and $32 price target.
11/21/16
JEFF
11/21/16
INITIATION
Target $25
JEFF
Buy
RA Pharmaceuticals initiated with a Buy at Jefferies
Jefferies analyst Eun Yang started RA Pharmaceuticals with a Buy rating and $25 price target. The analyst sees greater than 100% potential upside should the Phase II data for RA101495 in paroxysmal nocturnal hemoglobinuria patients be positive in the second half of 2017.
11/21/16
FBCO
11/21/16
INITIATION
Target $19
FBCO
Outperform
RA Pharmaceuticals initiated with an Outperform at Credit Suisse
Credit Suisse analyst Kennen MacKay initiated RA Pharmaceuticals with an Outperform and a $19 price target. The analyst said RA101495 as an attractive drug candidate for patients with paroxysmal nocturnal hemoglobinuria with potential to capture greater than30% market share in patients with unmet need despite Soliris treatment and sees potential peak global sales of $837M.
ZTO ZTO Express
$16.57

0.27 (1.66%)

11/21/16
GSCO
11/21/16
INITIATION
Target $19
GSCO
Buy
ZTO Express initiated with a Buy at Goldman
Goldman Sachs analyst Ronald Keung started ZTO Express with a Buy rating and $19 price target. The company is a leading e-commerce express courier in China with cost leadership, Keung tells investors in a research note.
11/21/16
MSCO
11/21/16
INITIATION
MSCO
Overweight
ZTO Express initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Edward Xu initiated ZTO Express with an Overweight and a $20 price target.
11/21/16
SBSH
11/21/16
INITIATION
Target $19.72
SBSH
Buy
ZTO Express initiated with a Buy at Citi
Citi analyst Vivian Tao started ZTO Express with a Buy rating and $19.72 price target. The analyst expects ZTO's growth momentum to continue as express volumes in China rise at a 30.5% annual rate over 2015-2020.

TODAY'S FREE FLY STORIES

PTLA

Portola Pharmaceuticals

$56.57

1.62 (2.95%)

12:51
09/19/17
09/19
12:51
09/19/17
12:51
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

FCAU

Fiat Chrysler

$17.10

0.275 (1.64%)

12:49
09/19/17
09/19
12:49
09/19/17
12:49
Hot Stocks
FCA US recalling 443,712 U.S.-market heavy-duty pickups, medium-duty trucks »

FCA US LLC is voluntarily…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$75.16

-0.15 (-0.20%)

12:48
09/19/17
09/19
12:48
09/19/17
12:48
Hot Stocks
Microsoft Azure IP Advantage available in China on October 1 »

Microsoft said on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Oct

AA

Alcoa

$45.77

0.86 (1.91%)

12:45
09/19/17
09/19
12:45
09/19/17
12:45
Options
Alcoa call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$4.15

-0.25 (-5.68%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37
Conference/Events
Noodles & Company management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ENDP

Endo

$8.34

-0.26 (-3.02%)

, JNJ

Johnson & Johnson

$135.14

-0.24 (-0.18%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37
Hot Stocks
Schneiderman, coalition of AGs expand multistate probe into opioid crisis »

New York Attorney General…

ENDP

Endo

$8.34

-0.26 (-3.02%)

JNJ

Johnson & Johnson

$135.14

-0.24 (-0.18%)

TEVA

Teva

$17.14

0.15 (0.88%)

AGN

Allergan

$218.48

-3.06 (-1.38%)

ABC

AmerisourceBergen

$80.24

-0.43 (-0.53%)

CAH

Cardinal Health

$66.37

-0.7 (-1.04%)

MCK

McKesson

$150.02

1.6 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 27

    Sep

  • 17

    Oct

LXRX

Lexicon

$12.81

0.44 (3.56%)

, IPSEY

Ipsen

$33.04

-0.36 (-1.08%)

12:37
09/19/17
09/19
12:37
09/19/17
12:37
Hot Stocks
Lexicon announces European Commission approves Xermelo »

Lexicon Pharmaceuticals…

LXRX

Lexicon

$12.81

0.44 (3.56%)

IPSEY

Ipsen

$33.04

-0.36 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

12:35
09/19/17
09/19
12:35
09/19/17
12:35
General news
Today's U.S. reports »

Today's U.S. reports…

LEG

Leggett & Platt

$45.25

-0.635 (-1.38%)

12:34
09/19/17
09/19
12:34
09/19/17
12:34
Conference/Events
Leggett & Platt management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

, VIA

Viacom

$37.45

-0.4 (-1.06%)

12:32
09/19/17
09/19
12:32
09/19/17
12:32
Periodicals
Viacom leak may have compromised digital properties, Gizmodo reports »

A security researcher…

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

VIA

Viacom

$37.45

-0.4 (-1.06%)

VIAB

Viacom

$27.32

-0.35 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

ACTG

Acacia Research

12:32
09/19/17
09/19
12:32
09/19/17
12:32
Hot Stocks
Acacia Research shares trade higher amid insider buying »

A number of insiders at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDOT

Green Dot

$48.82

0.79 (1.64%)

12:30
09/19/17
09/19
12:30
09/19/17
12:30
Conference/Events
Green Dot management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ADBE

Adobe

$155.77

1.28 (0.83%)

12:30
09/19/17
09/19
12:30
09/19/17
12:30
Options
Adobe attracts a pre-earnings call writer »

Adobe attracts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 22

    Oct

ENDP

Endo

$8.34

-0.26 (-3.02%)

, JNJ

Johnson & Johnson

$134.95

-0.43 (-0.32%)

12:28
09/19/17
09/19
12:28
09/19/17
12:28
Hot Stocks
Michigan AG says 41 state attorneys general now involved in opioid probe »

Michigan Attorney General…

ENDP

Endo

$8.34

-0.26 (-3.02%)

JNJ

Johnson & Johnson

$134.95

-0.43 (-0.32%)

TEVA

Teva

$17.14

0.15 (0.88%)

AGN

Allergan

$218.49

-3.05 (-1.38%)

ABC

AmerisourceBergen

$80.20

-0.47 (-0.58%)

CAH

Cardinal Health

$66.36

-0.71 (-1.06%)

MCK

McKesson

$149.89

1.47 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 27

    Sep

  • 17

    Oct

EFX

Equifax

$94.55

0.17 (0.18%)

12:27
09/19/17
09/19
12:27
09/19/17
12:27
Periodicals
Massachusetts Attorney General files lawsuit against Equifax, Reuters reports »

The State of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

ADK

AdCare

$0.98

-0.01 (-1.01%)

12:26
09/19/17
09/19
12:26
09/19/17
12:26
Conference/Events
AdCare to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDIT

Editas Medicine

$21.37

0.43 (2.05%)

12:26
09/19/17
09/19
12:26
09/19/17
12:26
Conference/Events
Editas Medicine management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

BBRY

BlackBerry

$9.26

-0.01 (-0.11%)

12:25
09/19/17
09/19
12:25
09/19/17
12:25
Options
BlackBerry call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

CARB

Carbonite

$21.70

1.2 (5.85%)

12:25
09/19/17
09/19
12:25
09/19/17
12:25
Conference/Events
Carbonite to hold financial analyst and investor day »

Financial Analyst and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

12:25
09/19/17
09/19
12:25
09/19/17
12:25
Conference/Events
The Board of Governors of the Federal Reserve System holds a closed meeting »

The Board of Governors of…

DWDP

DowDuPont

$69.92

0.15 (0.21%)

12:22
09/19/17
09/19
12:22
09/19/17
12:22
Conference/Events
DowDuPont management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

MTFB

Motif Bio

$8.18

0.168 (2.10%)

12:19
09/19/17
09/19
12:19
09/19/17
12:19
Conference/Events
Motif Bio analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIC

Macquarie Infrastructure

$73.80

-0.57 (-0.77%)

12:17
09/19/17
09/19
12:17
09/19/17
12:17
Conference/Events
Macquarie Infrastructure management to meet with SunTrust »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

$NSD

NASDAQ Market Internals

12:17
09/19/17
09/19
12:17
09/19/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$61.80

0.63 (1.03%)

, S

Sprint

$8.39

0.71 (9.24%)

12:16
09/19/17
09/19
12:16
09/19/17
12:16
General news
On The Fly: Top stock stories at midday »

Stocks were mildly higher…

TMUS

T-Mobile

$61.80

0.63 (1.03%)

S

Sprint

$8.39

0.71 (9.24%)

VZ

Verizon

$49.28

1.1869 (2.47%)

BOBE

Bob Evans

$72.93

1.02 (1.42%)

POST

Post Holdings

$86.28

0.44 (0.51%)

RAD

Rite Aid

$2.46

-0.27 (-9.89%)

WBA

Walgreens Boots Alliance

$82.60

0.1 (0.12%)

KSS

Kohl's

$45.65

0.76 (1.69%)

AMZN

Amazon.com

$974.19

-12.6 (-1.28%)

SCS

Steelcase

$14.63

0.275 (1.92%)

AZO

AutoZone

$537.84

-25.56 (-4.54%)

SNCR

Synchronoss

$16.75

0.64 (3.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 21

    Sep

  • 22

    Sep

  • 27

    Sep

  • 28

    Sep

  • 02

    Oct

  • 22

    Oct

  • 25

    Oct

  • 26

    Oct

  • 30

    Oct

  • 09

    Nov

  • 16

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.